Immunology meets neuroscience - Opportunities for immune intervention in neurodegenerative diseases

Brain, Behavior, and Immunity

Volumn 26, Issue 1, 2012, Pages 1-10

  Lynch, Marina A ^a   Mills, Kingston H G ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Alzheimer's disease; Immune therapy; Multiple sclerosis; Neurodegeneration; Neuroinflammation; T cells

Indexed keywords

ALEMTUZUMAB; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERFERON REGULATORY FACTOR; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MYELIN; NATALIZUMAB; RITUXIMAB; TOLL LIKE RECEPTOR;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ASTROCYTOSIS; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; COGNITION; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MENINGOENCEPHALITIS; MICROGLIA; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROSCIENCE; NONHUMAN; PARKINSON DISEASE; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ADAPTIVE IMMUNITY; ALLERGY AND IMMUNOLOGY; ALZHEIMER DISEASE; ANIMALS; ANTIBODIES; CENTRAL NERVOUS SYSTEM; DENDRITIC CELLS; HUMANS; MACROPHAGES; MICROGLIA; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; NEUROIMMUNOMODULATION; NEUROSCIENCES; T-LYMPHOCYTES; VACCINES;

EID: 81355138814     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2011.05.013     Document Type: Review

References (114)

1. Ajami B., Bennett J.L., Krieger C., Tetzlaff W., Rossi F.M. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci. 2007, 10:1538-1543.
2. Bach P., Tschape J.A., Kopietz F., Braun G., Baade J.K., Wiederhold K.H., Staufenbiel M., Prinz M., Deller T., Kalinke U., Buchholz C.J., Muller U.C. Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice. J. Immunol. 2009, 182:7613-7624.
3. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6:916-919.
4. Bechmann I., Steiner B., Gimsa U., Mor G., Wolf S., Beyer M., Nitsch R., Zipp F. Astrocyte-induced T cell elimination is CD95 ligand dependent. J. Neuroimmunol. 2002, 132:60-65.
5. Bettelli E., Sullivan B., Szabo S.J., Sobel R.A., Glimcher L.H., Kuchroo V.K. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J. Exp. Med. 2004, 200:79-87.
6. Breitner J.C., Haneuse S.J., Walker R., Dublin S., Crane P.K., Gray S.L., Larson E.B. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 2009, 72:1899-1905.
7. Brereton C.F., Sutton C.E., Lalor S.J., Lavelle E.C., Mills K.H. Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease. J. Immunol. 2009, 183:1715-1723.
8. Carson M.J., Thrash J.C., Lo D. Analysis of microglial gene expression: identifying targets for CNS neurodegenerative and autoimmune disease. Am. J. Pharmacogenomics 2004, 4:321-330.
9. Chen Y., Hancock W.W., Marks R., Gonnella P., Weiner H.L. Mechanisms of recovery from experimental autoimmune encephalomyelitis: T cell deletion and immune deviation in myelin basic protein T cell receptor transgenic mice. J. Neuroimmunol. 1998, 82:149-159.
10. Coles A.J., Compston D.A., Selmaj K.W., Lake S.L., Moran S., Margolin D.H., Norris K., Tandon P.K. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 2008, 359:1786-1801.
11. Coles A.J., Wing M.G., Molyneux P., Paolillo A., Davie C.M., Hale G., Miller D., Waldmann H., Compston A. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 1999, 46:296-304.
12. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., Zurawski S., Wiekowski M., Lira S.A., Gorman D., Kastelein R.A., Sedgwick J.D. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
13. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2001, 98:8850-8855.
14. Desai B.S., Monahan A.J., Carvey P.M., Hendey B. Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant. 2007, 16:285-299.
15. Ezzat M.K., Hann C.R., Vuk-Pavlovic S., Pulido J.S. Immune cells in the human choroid. Br. J. Ophthalmol. 2008, 92:976-980.
16. Fan R., Xu F., Previti M.L., Davis J., Grande A.M., Robinson J.K., Van Nostrand W.E. Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J. Neurosci. 2007, 27:3057-3063.
17. Ferrer I., Boada Rovira M., Sanchez Guerra M.L., Rey M.J., Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004, 14:11-20.
18. Fiala, M., Lin, J., Ringman, J., Kermani-Arab, V., Tsao, G., Patel, A., Lossinsky, A.S., Graves, M.C., Gustavson, A., Sayre, J., Sofroni, E., Suarez, T., Chiappelli, F., Bernard, G., 2005. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J. Alzheimers. Dis. 7, 221-232 (Discussion 255-262).
19. Fisher Y., Nemirovsky A., Baron R., Monsonego A. T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease. PLoS ONE 2010, 5:e10830.
20. Fletcher J.M., Lalor S.J., Sweeney C.M., Tubridy N., Mills K.H. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 2010, 162:1-11.
21. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis - the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354:942-955.
22. Garcia-Alloza M., Ferrara B.J., Dodwell S.A., Hickey G.A., Hyman B.T., Bacskai B.J. A limited role for microglia in antibody mediated plaque clearance in APP mice. Neurobiol. Dis. 2007, 28:286-292.
23. Gocke A.R., Cravens P.D., Ben L.H., Hussain R.Z., Northrop S.C., Racke M.K., Lovett-Racke A.E. T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J. Immunol. 2007, 178:1341-1348.
24. Halle A., Hornung V., Petzold G.C., Stewart C.R., Monks B.G., Reinheckel T., Fitzgerald K.A., Latz E., Moore K.J., Golenbock D.T. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 2008, 9:857-865.
25. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., Weaver C.T. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005, 6:1123-1132.
26. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688.
27. Hawker K., O'Connor P., Freedman M.S., Calabresi P.A., Antel J., Simon J., Hauser S., Waubant E., Vollmer T., Panitch H., Zhang J., Chin P., Smith C.H. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 2009, 66:460-471.
28. Henderson A.P., Barnett M.H., Parratt J.D., Prineas J.W. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann. Neurol. 2009, 66:739-753.
29. Hickman S.E., Allison E.K., El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 2008, 28:8354-8360.
30. Hickman S.E., El Khoury J. Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease. CNS Neurol. Disord. Drug Targets 2010, 9:168-173.
31. Hohlfeld R., Barkhof F., Polman C. Future clinical challenges in multiple sclerosis: relevance to sphingosine 1-phosphate receptor modulator therapy. Neurology 2011, 76:S28-37.
32. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
33. Jain P., Coisne C., Enzmann G., Rottapel R., Engelhardt B. Alpha4beta1 integrin mediates the recruitment of immature dendritic cells across the blood-brain barrier during experimental autoimmune encephalomyelitis. J. Immunol. 2010, 184:7196-7206.
34. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
35. Jones J.L., Coles A.J. Spotlight on alemtuzumab. Int. MS J. 2009, 16:77-81.
36. Kapsenberg M.L. Gammadelta T cell receptors without a job. Immunity 2009, 31:181-183.
37. Kaunzner U.W., Miller M.M., Gottfried-Blackmore A., Gal-Toth J., Felger J.C., McEwen B.S., Bulloch K. Accumulation of resident and peripheral dendritic cells in the aging CNS. Neurobiol. Aging 2010.
38. Khoruts A., Miller S.D., Jenkins M.K. Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells. J. Immunol. 1995, 155:5011-5017.
39. Koenigsknecht-Talboo J., Landreth G.E. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 2005, 25:8240-8249.
40. Koenigsknecht-Talboo J., Meyer-Luehmann M., Parsadanian M., Garcia-Alloza M., Finn M.B., Hyman B.T., Bacskai B.J., Holtzman D.M. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J. Neurosci. 2008, 28:14156-14164.
41. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., Sudo K., Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177:566-573.
42. Krakowski M., Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol. 1996, 26:1641-1646.
43. Kroenke M.A., Carlson T.J., Andjelkovic A.V., Segal B.M. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 2008, 205:1535-1541.
44. Kurzeja M., Rudnicka L., Olszewska M. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am. J. Clin. Dermatol. 2011, 12:113-125.
45. Lalor, S.J., Dungan, L., Sutton, C.E., Basdeo, S.A., Fletcher, J.M., Mills, K.H.G., 2011. in press. Caspase-1 processed cytokines IL-1β and IL-18 promote IL-17-production by γδ and CD4 T cells that mediate autoimmunity. J. Immunol.
46. Langer-Gould A., Atlas S.W., Green A.J., Bollen A.W., Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 2005, 353:375-381.
47. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201:233-240.
48. Lemere C.A. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Prog. Brain Res. 2009, 175:83-93.
49. Li M., Shang D.S., Zhao W.D., Tian L., Li B., Fang W.G., Zhu L., Man S.M., Chen Y.H. Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. J. Immunol. 2009, 182:5778-5788.
50. Liu Y.J., Guo D.W., Tian L., Shang D.S., Zhao W.D., Li B., Fang W.G., Zhu L., Chen Y.H. Peripheral T cells derived from Alzheimer's disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-alpha-dependent. Neurobiol. Aging 2010, 31:175-188.
51. Loewenbrueck K.F., Tigno-Aranjuez J.T., Boehm B.O., Lehmann P.V., Tary-Lehmann M. Th1 responses to beta-amyloid in young humans convert to regulatory IL-10 responses in Down syndrome and Alzheimer's disease. Neurobiol. Aging 2010, 31:1732-1742.
52. Lynch M.A. Age-related neuroinflammatory changes negatively impact on neuronal function. Front Aging Neurosci. 2010, 1:6.
53. Mackic J.B., Weiss M.H., Miao W., Kirkman E., Ghiso J., Calero M., Bading J., Frangione B., Zlokovic B.V. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. J. Neurochem. 1998, 70:210-215.
54. Man S.M., Ma Y.R., Shang D.S., Zhao W.D., Li B., Guo D.W., Fang W.G., Zhu L., Chen Y.H. Peripheral T cells overexpress MIP-1alpha to enhance its transendothelial migration in Alzheimer's disease. Neurobiol. Aging 2007, 28:485-496.
55. Matusevicius D., Kivisakk P., He B., Kostulas N., Ozenci V., Fredrikson S., Link H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler. 1999, 5:101-104.
56. McGeer P.L., Itagaki S., McGeer E.G. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol. 1988, 76:550-557.
57. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996, 47:425-432.
58. McMenamin P.G., Wealthall R.J., Deverall M., Cooper S.J., Griffin B. Macrophages and dendritic cells in the rat meninges and choroid plexus: three-dimensional localisation by environmental scanning electron microscopy and confocal microscopy. Cell Tissue Res. 2003, 313:259-269.
59. McQuillan K., Lynch M.A., Mills K.H. Activation of mixed glia by Abeta-specific Th1 and Th17 cells and its regulation by Th2 cells. Brain Behav. Immun. 2010, 24:598-607.
60. Milder D.G. Progression of disease and a remedy: causative role of macrophages and microglia: remedial effect of immunomodulatory and immunosuppressive therapies "in combination" Med. Hypotheses 2006, 67:736-739.
61. Mills K.H. Induction, function and regulation of IL-17-producing T cells. Eur. J. Immunol. 2008, 38:2636-2649.
62. Monsonego A., Weiner H.L. Immunotherapeutic approaches to Alzheimer's disease. Science 2003, 302:834-838.
63. Morgan D. Immunotherapy for Alzheimer's disease. J. Alzheimers Dis. 2006, 9:425-432.
64. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
65. Murphy A.C., Lalor S.J., Lynch M.A., Mills K.H. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav. Immun. 2010, 24:641-651.
66. Neumann H., Kotter M.R., Franklin R.J. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 2009, 132:288-295.
67. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
68. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., Wang Y., Hood L., Zhu Z., Tian Q., Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 2005, 6:1133-1141.
69. Petrushina I., Ghochikyan A., Mktrichyan M., Mamikonyan G., Movsesyan N., Davtyan H., Patel A., Head E., Cribbs D.H., Agadjanyan M.G. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J. Neurosci. 2007, 27:12721-12731.
70. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., Toal M., Lynn F., Panzara M.A., Sandrock A.W. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354:899-910.
71. Popescu B.O., Toescu E.C., Popescu L.M., Bajenaru O., Muresanu D.F., Schultzberg M., Bogdanovic N. Blood-brain barrier alterations in ageing and dementia. J. Neurol. Sci. 2009, 283:99-106.
72. Popovich P.G., van Rooijen N., Hickey W.F., Preidis G., McGaughy V. Hematogenous macrophages express CD8 and distribute to regions of lesion cavitation after spinal cord injury. Exp. Neurol. 2003, 182:275-287.
73. Pul R., Dodel R., Stangel M. Antibody-based therapy in Alzheimer's disease. Expert Opin. Biol. Ther. 2011, 11:343-357.
74. Qin W., Ho L., Pompl P.N., Peng Y., Zhao Z., Xiang Z., Robakis N.K., Shioi J., Suh J., Pasinetti G.M. Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. J. Biol. Chem. 2003, 278:50970-50977.
75. Reed-Geaghan E.G., Reed Q.W., Cramer P.E., Landreth G.E. Deletion of CD14 attenuates Alzheimer's disease pathology by influencing the brain's inflammatory milieu. J. Neurosci. 2010, 30:15369-15373.
76. Richard K.L., Filali M., Prefontaine P., Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J. Neurosci. 2008, 28:5784-5793.
77. Rivest S. Regulation of innate immune responses in the brain. Nat. Rev. Immunol. 2009, 9:429-439.
78. Rodriguez M., Scheithauer B. Ultrastructure of multiple sclerosis. Ultrastruct. Pathol. 1994, 18:3-13.
79. Rudick R.A., Trapp B.D. Gray-matter injury in multiple sclerosis. N. Engl. J. Med. 2009, 361:1505-1506.
80. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 2002, 3:824-828.
81. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
82. Schindowski K., Eckert A., Peters J., Gorriz C., Schramm U., Weinandi T., Maurer K., Frolich L., Muller W.E. Increased T-cell reactivity and elevated levels of CD8+ memory T-cells in Alzheimer's disease-patients and T-cell hyporeactivity in an Alzheimer's disease-mouse model: implications for immunotherapy. Neuromolecular Med. 2007, 9:340-354.
83. Segal B.M., Constantinescu C.S., Raychaudhuri A., Kim L., Fidelus-Gort R., Kasper L.H. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008, 7:796-804.
84. Seguin R., Biernacki K., Prat A., Wosik K., Kim H.J., Blain M., McCrea E., Bar-Or A., Antel J.P. Differential effects of Th1 and Th2 lymphocyte supernatants on human microglia. Glia 2003, 42:36-45.
85. Shaftel S.S., Kyrkanides S., Olschowka J.A., Miller J.N., Johnson R.E., O'Banion M.K. Sustained hippocampal IL-1beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J. Clin. Invest. 2007, 117:1595-1604.
86. Siffrin V., Vogt J., Radbruch H., Nitsch R., Zipp F. Multiple sclerosis - candidate mechanisms underlying CNS atrophy. Trends Neurosci. 2010, 33:202-210.
87. Simard A.R., Rivest S. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. Faseb J. 2004, 18:998-1000.
88. Simard A.R., Soulet D., Gowing G., Julien J.P., Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006, 49:489-502.
89. Sta M., Sylva-Steenland R.M., Casula M., de Jong J.M., Troost D., Aronica E., Baas F. Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol. Dis. 2011.
90. Stamatovic S.M., Keep R.F., Andjelkovic A.V. Brain endothelial cell-cell junctions: how to "open" the blood brain barrier. Curr. Neuropharmacol. 2008, 6:179-192.
91. Stephens L.A., Malpass K.H., Anderton S.M. Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg. Eur. J. Immunol. 2009, 39:1108-1117.
92. Stewart W.F., Kawas C., Corrada M., Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997, 48:626-632.
93. Stone D.K., Reynolds A.D., Mosley R.L., Gendelman H.E. Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid. Redox Signal. 2009, 11:2151-2166.
94. Streit W.J., Braak H., Xue Q.S., Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol. 2009, 118:475-485.
95. Streit W.J., Miller K.R., Lopes K.O., Njie E. Microglial degeneration in the aging brain - bad news for neurons?. Front Biosci. 2008, 13:3423-3438.
96. Stys P.K. Multiple sclerosis: autoimmune disease or autoimmune reaction?. Can. J. Neurol. Sci. 2010, 37(Suppl. 2):S16-S23.
97. Sung S., Yang H., Uryu K., Lee E.B., Zhao L., Shineman D., Trojanowski J.Q., Lee V.M., Pratico D. Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am. J. Pathol. 2004, 165:2197-2206.
98. Sutton C., Brereton C., Keogh B., Mills K.H., Lavelle E.C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 2006, 203:1685-1691.
99. Sutton C.E., Lalor S.J., Sweeney C.M., Brereton C.F., Lavelle E.C., Mills K.H. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T Cells, amplifying Th17 responses and autoimmunity. Immunity 2009, 31:331-341.
100. Sweeney C.M., Lonergan R., Basdeo S.A., Kinsella K., Dungan L.S., Higgins S.C., Kelly P.J., Costelloe L., Tubridy N., Mills K.H., Fletcher J.M. IL-27 mediates the response to IFN-beta therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav. Immun. 2011.
101. Tahara K., Kim H.D., Jin J.J., Maxwell J.A., Li L., Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 2006, 129:3006-3019.
102. Tian L., Rauvala H., Gahmberg C.G. Neuronal regulation of immune responses in the central nervous system. Trends Immunol. 2009, 30:91-99.
103. Togo T., Akiyama H., Iseki E., Kondo H., Ikeda K., Kato M., Oda T., Tsuchiya K., Kosaka K. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J. Neuroimmunol. 2002, 124:83-92.
104. Trieb K., Ransmayr G., Sgonc R., Lassmann H., Grubeck-Loebenstein B. APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol. Aging 1996, 17:541-547.
105. Vaknin-Dembinsky A., Balashov K., Weiner H.L. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J. Immunol. 2006, 176:7768-7774.
106. Vellas B., Black R., Thal L.J., Fox N.C., Daniels M., McLennan G., Tompkins C., Leibman C., Pomfret M., Grundman M. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 2009, 6:144-151.
107. Vercellino M., Masera S., Lorenzatti M., Condello C., Merola A., Mattioda A., Tribolo A., Capello E., Mancardi G.L., Mutani R., Giordana M.T., Cavalla P. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J. Neuropathol. Exp. Neurol. 2009, 68:489-502.
108. Walker D., Lue L.F. Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. Curr. Neuropharmacol. 2007, 5:232-243.
109. Weiner H.L., Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat. Rev. Immunol. 2006, 6:404-416.
110. Wilcock D.M., Rojiani A., Rosenthal A., Levkowitz G., Subbarao S., Alamed J., Wilson D., Wilson N., Freeman M.J., Gordon M.N., Morgan D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 2004, 24:6144-6151.
111. Xiang Z., Ho L., Yemul S., Zhao Z., Qing W., Pompl P., Kelley K., Dang A., Teplow D., Pasinetti G.M. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr. 2002, 10:271-278.
112. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A.L., Citron M., Landreth G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 2003, 23:7504-7509.
113. Yao Z., Painter S.L., Fanslow W.C., Ulrich D., Macduff B.M., Spriggs M.K., Armitage R.J. Human IL-17: a novel cytokine derived from T cells. J. Immunol. 1995, 155:5483-5486.
114. Zhao C., Li W.W., Franklin R.J. Differences in the early inflammatory responses to toxin-induced demyelination are associated with the age-related decline in CNS remyelination. Neurobiol. Aging 2006, 27:1298-1307.